Testosterone replacement therapy suppresses the hypothalamic-pituitary-testicular axis and can impair fertility. This well-known side effect has driven interest in peptide-based alternatives that preserve natural hormone production. The market has responded with enthusiasm. The evidence has responded more cautiously.
This article reviews peptide therapies for men's health with explicit evidence grades and regulatory status. It is not a guide to using these compounds. It is a guide to understanding what has been proven and what has not.
Kisspeptin: restoring natural testosterone production
Kisspeptin is a hypothalamic neuropeptide that stimulates GnRH neurons, triggering the cascade that produces luteinizing hormone, follicle-stimulating hormone, and ultimately testosterone. Unlike exogenous testosterone, kisspeptin does not suppress the HPT axis. It activates it.
Clinical studies show that kisspeptin-10 infusion increases LH and testosterone in healthy men and in men with hypogonadotropic hypogonadism. A 2018 study by Young and colleagues demonstrated dose-dependent increases in LH, FSH, and testosterone in men with idiopathic hypogonadotropic hypogonadism (PMID: 30590872). The effect is real. The practicality is limited. Kisspeptin requires frequent subcutaneous injection or continuous infusion, and no oral formulation exists. It is not FDA approved for any indication. The practical barrier to kisspeptin use is administration: it requires multiple daily injections or a continuous subcutaneous infusion pump, making it far less convenient than a weekly testosterone injection or daily testosterone gel. Until a longer-acting formulation is developed, kisspeptin is unlikely to replace standard testosterone therapy for most patients.
- Mechanism: Activates GnRH neurons via KISS1R receptor
- Effect: Dose-dependent increase in LH, FSH, and testosterone
- Route: Subcutaneous injection or infusion
- Evidence: Phase I and II trials in men; not yet FDA approved
- Advantage: Preserves fertility and testicular function
Bremelanotide for sexual dysfunction
Bremelanotide, sold as Vyleesi, is a melanocortin receptor agonist approved by the FDA in 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Its mechanism involves activation of MC4R and MC1R receptors in the central nervous system, increasing sexual arousal through brain pathways rather than peripheral vasodilation like sildenafil or tadalafil.
For men, early-phase trials showed promising results for erectile dysfunction. The mechanism is genuinely different from PDE5 inhibitors and might help men who do not respond to Viagra or Cialis. However, larger confirmatory trials in men were not completed, and bremelanotide is not FDA approved for male erectile dysfunction. The nausea rate of approximately 40% is also a significant barrier to patient acceptance. For a medication intended to enhance sexual experience, a side effect that causes vomiting in two out of five users is a major limitation. This explains why bremelanotide has not been developed further for male sexual dysfunction.
- Approved: Yes for women with HSDD under the brand Vyleesi
- Male ED: Phase II data exists but not approved by FDA
- Mechanism: Central nervous system melanocortin activation
- Side effects: Nausea in approximately 40%, flushing, transient blood pressure elevation
- Route: Subcutaneous injection only
Gonadorelin and hCG for fertility preservation
Gonadorelin is the natural hypothalamic hormone that triggers LH and FSH release. In pulsatile administration, one pulse every 90 to 120 minutes, it can restore fertility in men with hypogonadotropic hypogonadism. Continuous administration causes receptor downregulation and paradoxically suppresses the axis, making it useless for chronic replacement.
Human chorionic gonadotropin mimics LH and directly stimulates Leydig cells to produce testosterone. It is FDA approved for hypogonadism and is commonly used to maintain fertility and testicular volume in men on testosterone replacement therapy. hCG is the standard of care for this indication, not an experimental peptide.
- Gonadorelin: Pulsatile administration only; impractical for chronic use; FDA approved for diagnostic use
- hCG: Direct LH mimic; maintains testicular size and fertility; standard adjunct to TRT
- Both preserve HPT axis function unlike exogenous testosterone
Tesamorelin: body composition in HIV lipodystrophy
Tesamorelin, sold as Egrifta, is a GHRH analog FDA approved for HIV-associated lipodystrophy. It increases endogenous growth hormone release, which reduces visceral adipose tissue and increases lean body mass in HIV-infected patients with abnormal fat distribution. It is not approved for general anti-aging or body composition enhancement in healthy populations.
Testosterone replacement: still the standard
Testosterone cypionate and enanthate have been used for over 70 years. They are effective, inexpensive, and well-characterized. For men with primary hypogonadism, meaning the testicles themselves cannot produce adequate testosterone, exogenous testosterone is the only pharmacological solution. No peptide can fix a testicle that does not work.
The fertility concern is real but manageable. Men who desire fertility while on TRT can add hCG to their regimen. This is standard of care, not experimental. Clomiphene citrate, a selective estrogen receptor modulator, is another established option that stimulates endogenous testosterone production while preserving fertility. These are not peptides, but they are proven. They are also significantly less expensive and more accessible than research peptides from unregulated suppliers.
What we do not know
The major unknown in peptide therapy for men's health is long-term safety. Kisspeptin has been administered in short clinical trials lasting days to weeks. No study has followed kisspeptin-treated patients for years. The effects of chronic KISS1R stimulation on the pituitary, testes, and prostate are unknown. The same is true for chronic melanocortin stimulation with bremelanotide.
Another unknown is optimal dosing. Peptide pharmacokinetics are complex, with rapid degradation, variable absorption, and individual differences in receptor sensitivity. The doses used in online protocols are often extrapolated from animal models or small human studies, not validated in large populations. What works in a 20-person Phase I trial may not work, or may be unsafe, in broader use. The compounding pharmacy restrictions that took effect in 2025 have also made many of these peptides harder to obtain legally, pushing patients toward research chemical suppliers with no quality oversight. This creates a dual risk: unknown pharmacology plus unknown product quality.
What the evidence actually says
For men with hypogonadism, testosterone replacement remains the standard of care with the largest evidence base. Peptides offer theoretical advantages, primarily fertility preservation, but none have matched testosterone's efficacy for symptom relief in primary hypogonadism. Kisspeptin is interesting but impractical. Bremelanotide is approved for women, not men. Gonadorelin requires a pump. hCG works but is already standard care. Tesamorelin is restricted to HIV lipodystrophy.
The honest summary is that peptide therapies for men's health are mostly promising but unproven, with the exception of hCG which is already established. Patients seeking alternatives to testosterone should discuss hCG, clomiphene, and kisspeptin with an endocrinologist who can evaluate individual fertility goals and medical history. Self-experimentation with research peptides is not a substitute for proper endocrine evaluation. Before spending money on unproven compounds, men should first address sleep, exercise, body composition, and stress management. These fundamentals affect natural testosterone production more than most patients realize, and they cost nothing. A blood test for total and free testosterone, LH, FSH, and estradiol typically costs less than one vial of research peptides and provides more actionable information. Start with proper testing and data, not unproven drugs.